Evidence map›Paper›PMID 36506748›Full record

ReviewTherapeutic advances in gastroenterology2022

Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective.

Jin Guo, Chun-Xia Shi, Qing-Qi Zhang, Wei Deng, Lu-Yi Zhang, Qian Chen, Dan-Mei Zhang, Zuo-Jiong Gong

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jin GuoDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Chun-Xia ShiDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Qing-Qi ZhangDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Wei DengDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Lu-Yi ZhangDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Qian ChenDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Dan-Mei ZhangDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Zuo-Jiong GongDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuchang District, Wuhan, Hubei 430060, China.ORCID https://orcid.org/0000-0002-4676-5856
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades, non-alcoholic fatty liver disease (NAFLD) has become a leading burden of hepatocellular carcinoma and liver transplantation. Although the exact pathogenesis of NAFLD has not been fully elucidated, recent hypotheses placed more emphasis on the crucial role of the gut microbiome and its derivatives. Reportedly, microbial metabolites such as short-chain fatty acids, amino acid metabolites (indole and its derivatives), bile acids (BAs), trimethylamine N-oxide (TMAO), and endogenous ethanol exhibit sophisticated bioactive properties. These molecules regulate host lipid, glucose, and BAs metabolic homeostasis

Indexed as

gastrointestinal microbiomemetabolitesnon-alcoholic fatty liver diseasetreatment options

Identifiers

PMID36506748
PMCPMC9730013
OpenAlexW4311280432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.